At the conclusion of this knowledge-based activity, participants will be able to:
  • Analyze the changing paradigm in clinical approaches to management of B-cell malignancies with BTK therapy and the implications for patient care.
  • Evaluate the respective safety and efficacy profiles of first- vs. second-generation BTK inhibitors.
  • Effectively incorporate BTK inhibitors into chronic management of B-cell malignancies.
  • Examine effective team-based strategies to improve patient adherence to oral chemotherapy.